PT - JOURNAL ARTICLE AU - CARL BLOMBERG AU - JONAS NILSSON AU - GEORG HOLGERSSON AU - PER EDLUND AU - MICHAEL BERGQVIST AU - LINDA ADWALL AU - SIMON EKMAN AU - DANIEL BRATTSTRÖM AU - STEFAN BERGSTRÖM TI - Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review DP - 2015 May 01 TA - Anticancer Research PG - 2493--2501 VI - 35 IP - 5 4099 - http://ar.iiarjournals.org/content/35/5/2493.short 4100 - http://ar.iiarjournals.org/content/35/5/2493.full SO - Anticancer Res2015 May 01; 35 AB - Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.